Top Markets
Coin of the day
Biocept, Inc. Biocept, Inc.

Biocept, Inc.

BIOC
Xếp hạng trong cổ phiếu #41381
Biocept, Inc. is a company specializing in molecular diagnostics for cancer,... Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies. This information is vital throughout the patient journey: at initial diagnosis, during disease progression, and for ongoing monitoring to detect the emergence of treatment resistance. Their diagnostic portfolio extends to various solid tumor types, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Beyond blood-based diagnostics, Biocept offers specialized testing services for cerebrospinal fluid (CSF), analyzing tumor cells, ctDNA, and ctRNA. These services cater to a broad spectrum of medical specialists, such as medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, and pathologists. Furthermore, the company supports pharmaceutical and biopharmaceutical companies, along with clinical research organizations (CROs), through its clinical trial and research services. Additionally, Biocept provides RT-PCR testing for COVID-19. In strategic partnerships, Biocept collaborates with CLEARED4 on a system designed to track and manage COVID-19 testing requirements and results for clients. Another collaboration involves Protean BioDiagnostics, Inc., focusing on research into the efficacy of Biocept's proprietary Target Selector molecular assay for determining EGFR status in non-small cell lung cancer (NSCLC) patients. Established in 1997, Biocept, Inc. operates from its headquarters in San Diego, California.
Giá cổ phiếu
$0.053
Đồng bộ lần cuối: 2023-11-21
Vốn hóa thị trường
$23.67K
Thay đổi (1 ngày)
-11.67%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Biocept, Inc. (BIOC)

Danh mục

Lịch sử chia tách cổ phiếu của Biocept, Inc. (BIOC)
Cổ phiếu Biocept, Inc. (mã: BIOC) đã trải qua tổng cộng 0 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Aug 13, 2026.
Một cổ phiếu BIOC mua trước ngày Aug 13, 2026 hiện tương đương với 0 cổ phiếu BIOC.
Danh sách chia tách cổ phiếu
Năm Chia tách Tỷ lệ Tỷ lệ cộng dồn
Không đủ dữ liệu cho ngày được cung cấp.
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
Công ty Số lần chia tách cổ phiếu Tỷ lệ cộng dồn Quốc gia
8 x34
US
7 x47
US
0 -
CN
4 x15
US
0 -
US